FDA Accepts NDA for Investigational Major Depressive Disorder Therapy
April 16th 2018Officials with the FDA have accepted a new drug application (NDA) for Alkermes once-daily, oral, investigative major depressive disorder (MDD) therapy, ALKS 5461, intended for use in patients with an inadequate response to standard antidepressant treatment.
Read More